Background Adjuvant chemotherapy is a key component of advanced ovarian cancer treatment, when surgery alone is not sufficient. Recurrence is common in ovarian cancer patients and most women require prolonged second-line and higher-line chemotherapy. With newer targeted therapies, modest improvements in survival and quality of life may be attained at substantial cost, but the relative economic efficiency of these newer agents remains unknown. Objective We undertook this systematic review to comprehensively evaluate the cost-effectiveness of various chemotherapeutic and targeted therapy alternatives for ovarian cancer. Methods We searched Medline, PubMed, and Embase databases to identify economic evaluations published over the last 18 years (1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014). From the 2513 unique papers retrieved, 74 full texts were selected for full-text review based on a priori eligibility criteria. Two authors independently reviewed these articles to determine eligibility for final review. The quality of the included studies was assessed using the Quality of Health Economic Studies (QHES). Results A total of 28 studies were included for reporting. Administration of intravenous cisplatin-paclitaxel combination chemotherapy for first-line treatment was the most cost-effective alternative (2014 US dollars [USD] equivalent incremental cost-effectiveness ratio [ICER] *US$17,000-US$27,000 per life year gained [LYG]), while the use of bevacizumab did not demonstrate similar value for money (2014 USD equivalent ICER was greater than US$200,000 per quality-adjusted life-year [QALY]). For second-line treatment, the use of platinum-paclitaxel combination or platinum monotherapy was cost-effective compared with platinum monotherapy or best supportive care, respectively, in women with recurrent platinum-sensitive disease. For patients with partial platinum sensitivity, pegylated liposomal doxorubicin (PLD) plus trabectedin may be cost-effective (2014 USD equivalent ICER was *US$57,000-US$62,000 per QALY) compared with PLD alone. For recurrent platinum-resistant cases, there was limited evidence to conclude the most valuable treatment; though one study showed that best supportive care was most cost-effective, while second-line monotherapy with doxorubicin (2014 USD equivalent ICER was *US$90,000 per LYG) may also be cost-effective compared with best supportive care. Conclusions Despite varying methodological approaches and multiple sources for cost and effectiveness inputs, this systematic review demonstrated that standard platinumtaxane combination chemotherapy for first-line treatment was most cost-effective. There was unanimous agreement that bevacizumab was not a cost-effective front-line therapy compared with platinum-taxane combination for the Electronic supplementary material The online version of this article
independently reviewed these articles to determine eligibility for final review. The quality of the included studies was assessed using the Quality of Health Economic Studies (QHES). Results A total of 28 studies were included for reporting.
Administration of intravenous cisplatin-paclitaxel combination chemotherapy for first-line treatment was the most cost-effective alternative (2014 US dollars [USD] equivalent incremental cost-effectiveness ratio [ICER]
*US$17,000-US$27,000 per life year gained [LYG] ), while the use of bevacizumab did not demonstrate similar value for money (2014 USD equivalent ICER was greater than US$200,000 per quality-adjusted life-year [QALY] ). For second-line treatment, the use of platinum-paclitaxel combination or platinum monotherapy was cost-effective compared with platinum monotherapy or best supportive care, respectively, in women with recurrent platinum-sensitive disease. For patients with partial platinum sensitivity, pegylated liposomal doxorubicin (PLD) plus trabectedin may be cost-effective (2014 USD equivalent ICER was *US$57,000-US$62,000 per QALY) compared with PLD alone. For recurrent platinum-resistant cases, there was limited evidence to conclude the most valuable treatment; though one study showed that best supportive care was most cost-effective, while second-line monotherapy with doxorubicin (2014 USD equivalent ICER was *US$90,000 per LYG) may also be cost-effective compared with best supportive care. Conclusions Despite varying methodological approaches and multiple sources for cost and effectiveness inputs, this systematic review demonstrated that standard platinumtaxane combination chemotherapy for first-line treatment was most cost-effective. There was unanimous agreement that bevacizumab was not a cost-effective front-line therapy compared with platinum-taxane combination for the overall ovarian cancer population, though its use in the high-use population may yield better value. For second-line treatment, platinum-based chemotherapy remained costeffective among patients with recurrent platinum-sensitive disease, while there was limited evidence to conclude the most valuable treatment alternative among patients with recurrent platinum-resistant disease. Future research incorporating real-world data is essential to corroborate findings from trial-based economic evaluations. In addition, for improving consistency in reporting and quality of studies, incorporating QALYs in this population is important, especially since chemotherapy is administered for lengthy periods of time.
Key Points
There is considerable variation in the type of costs included as well as the sources used to estimate the cost of treatment modalities resulting in different cost-effectiveness outcomes.
The review found that the cisplatin-paclitaxel combination was the most cost-effective first-line alternative; however, carboplatin is the preferred platinum-based chemotherapy agent, but costeffectiveness studies evaluating carboplatin are limited.
Targeted therapies like bevacizumab, although more effective compared with the platinum-taxane combination, were not found to be cost-effective.
For second-line treatment among recurrent platinumsensitive patients, platinum-based chemotherapy remained cost-effective, while evidence for recurrent platinum-resistant patients was limited.
Introduction
An estimated 21,980 new cases of ovarian cancer were diagnosed in the United States in 2014 and 65,500 new cases in Europe in 2012, accounting for 3-4 % of all cancers in women [1, 2] . Despite a decrease in incidence and mortality rates over the last few years, this malignancy continues to cause the highest number of gynecological related cancer deaths [1] . Survival rates in ovarian cancer are highly dependent on patient age and stage at diagnosis; elderly women (65? years) are half as likely to survive and patients with distant stage tumors are three times more likely to die within 5 years after diagnosis [3, 4] . Primarily diagnosed at an advanced stage (70 % cases), ovarian cancer overall poses a very poor prognosis [5] . Recurrence rates for stages III-IV are as high as 70-90 % [6] , making this malignancy almost non-curable, requiring maintenance and palliative chemotherapeutic treatments for lengthy periods of time.
The National Comprehensive Cancer Network (NCCN) guidelines recommend appropriate first-line surgical staging, debulking, and adjuvant systemic chemotherapy for treatment of ovarian cancer [5] . For tumors staged as IA or IB, surgery may be a sufficient treatment approach; however, for patients staged as IC or higher, administration of platinum-taxane combination adjuvant chemotherapy is recommended [3, 5] . Utilization of expensive newer targeted therapies (e.g., bevacizumab) and the prolonged use of chemotherapies may increase the overall economic burden of ovarian cancer. Thus, providing cost-effective first-line treatment and subsequent care is essential from both private and public standpoints. With the introduction of taxane in the late 1990s as part of routine combination treatment, several cost-effectiveness and cost-utility evaluations have been conducted for currently available treatment options. A few studies have previously reviewed the cost-effectiveness literature in ovarian cancer [7] [8] [9] [10] ; however, none of those had a formal systematic review approach. In addition, economic evaluations on newer targeted therapies have not been reviewed and summarized in the overall cost-effectiveness literature. In order to better inform decision makers and clinicians, the objective of this study was to synthesize evidence by conducting a systematic review of economic evaluations of chemotherapeutic and targeted treatment alternatives for ovarian cancer over the past 18 years and assess the quality of these studies.
Methods

Eligibility Criteria
The PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines by Moher et al. [11] were followed for review and reporting procedures. Studies eligible for inclusion represented full economic evaluations (i.e., cost-effectiveness analyses [CEA] or costutility analyses [CUA] ) that evaluated a chemotherapeutic or targeted therapy agent for the treatment of first-line (i.e., primary adjuvant or neoadjuvant) or subsequent-line ovarian cancer. Studies with partial economic evaluations, cost-minimization analyses or cost-benefit analyses were excluded. Studies were required to report both costs and survival outcomes (i.e., overall, progression-free or qualityadjusted survival). Research articles from journals published in the English language were included; comments, editorials, letters, news, correspondence, study protocols, case reports, case series, narrative and systematic reviews were excluded. We also excluded economic evaluations that assessed other aspects of care, such as screening, surgical treatment, or palliative care.
Information Sources and Search
Medline (Ovid), PubMed (NLM), and Embase (Ovid) were searched with the assistance of a public health librarian (HVV) experienced in developing search strategies for systematic reviews. Search concepts were economic evaluations, treatment (i.e., chemotherapy and targeted agents), and ovarian cancer. The search was last updated on August 31, 2014, and included articles published from 1996 (after the introduction of taxane for ovarian cancer) through 2014. Manufacturers or study authors were not contacted to identify any other unpublished sources of information. RefWorks (ProQuest) was used to store all citations found in the search process, and to check for duplicates. Search strategies and results were tracked using the PRIMARY Excel Workbook for Systematic Reviews [12] . Strategies for each database searched can be found in Appendix A (see electronic supplementary material).
Study Selection
Two authors (IBP and RCP) independently screened a random sample of 66 titles and abstracts for study eligibility in which they were blinded to authors and journal titles to reduce the potential bias for being influenced by author name or journal title, and they reached a moderate level of agreement on study eligibility (Cohen's j = 0.65, SE of j = 0.24) [13, 14] . Disagreement between the reviewers was resolved through discussion. After initial review, they independently screened all titles and abstracts, still blinded to authors and journal titles, using the Excel Workbook for 2 Screeners [15] . Decision data were compiled in a single Excel workbook and discrepancies were discussed by both reviewers until a consensus was reached regarding eligibility. The full text of the eligible articles was retrieved and reviewed independently by two authors (IBP and RCP) and the study was included for final review if it met all of the eligibility criteria (Fig. 1 ).
Data Collection Process and Data Items
A data-coding evidence table was developed to abstract citation, study, costs, and effectiveness information from each study. The evidence table was pilot tested on four studies by two coders (IBP and RCP) and evaluated for consistency by the principal investigator (DRL) prior to final use. Abstracted variables included first author, study population, study characteristics (e.g., perspective, time horizon, discount rate, model type, and sensitivity analysis), treatment arms (i.e., drug, dosage, and administration), source of effectiveness data, resource use and source of cost data, cost outcomes, effectiveness outcomes, incremental cost-effectiveness ratio (ICER), author's conclusion, and limitations. ICER values for all studies were converted to 2014 US dollars. For studies that were reported in US dollars, medical care consumer price index was used to adjust for inflation, and for studies that reported in currencies other than US dollars, purchasing power parity was used [16, 17] .
Quality Assessment
The 16-item validated Quality of Health Economic Studies (QHES) instrument [18] , which is based on Drummond's checklist and the United States Public Health Service Panel on Cost-Effectiveness in Health and Medicine, was used to assess the quality of the included studies. Two authors (IBP and RCP) independently reviewed the studies and scored each question as 1-yes or 0-no. To ensure consistency in the quality assessment, additional decisions similar to those used by Zhang et al. [19] were made and are shown in Table 3 . In addition to the objective quality assessment using the QHES instrument, a subjective assessment of each study was also conducted.
Results
Study Selection
A total of 4309 citations were found through the electronic database search process; approximately 40 % (j = 1796) were duplicate citations and were removed from further review. Of the remaining 2513 citations, 95 % (j = 2375) of the titles and abstracts were deemed ineligible during the screening process as they were not economic evaluations. Of the 74 papers that qualified for a full-text review, one was not available for review [20] and 45 did not meet the study eligibility criteria. The flowchart in Fig. 1 outlines the search results indicating exclusions at various stages of the review process. Twenty-eight publications were included in this systematic review . We have summarized the findings of these studies by type of treatment: first-line therapy (18 studies), maintenance therapy (1 study), second-line chemotherapy for recurrent platinumsensitive disease (7 studies), second-line chemotherapy for recurrent platinum-resistant disease (1 study), multiple-line chemotherapy regimen (1 study), and other treatment regimen (1 study).
First-Line Therapy
Cisplatin-Paclitaxel Compared with Cisplatin-
Cyclophosphamide (j = 8)
The earliest economic evaluations in ovarian cancer were conducted soon after clinical trial-based evidence by the US Gynaecologic Oncology Group (GOG) supported taxane as an appropriate first-line combination therapy with cisplatin. From 1996 to 1998 a series of cost-effectiveness evaluations compared the standard cisplatin-cyclophosphamide with cisplatin-paclitaxel for treatment of advanced ovarian cancer patients [21] [22] [23] [24] [25] . These studies were conducted in various countries and from varying healthcare perspectives. Results from the GOG-111 trial [49] formed the basis of clinical estimates for all studies except the study by Covens et al. [22] that used patient charts as their source of effectiveness data. Major cost categories included drug acquisition, administration, hospitalizations, adverse event management and follow-up monitoring. Table 1 provides details on specific cost inputs from each study. Two Canadian studies were conducted from the perspective of the Ministry of Health (Ontario) [22, 23] and one study from the Canadian healthcare system perspective [25] . The ICER estimates for these studies were Can$20,355 per life-year gained (LYG), Can$32,213 per LYG, and Can$11,600-Can$24,200 per quality-adjusted progression-free life-year (PFLY), depending on second-line treatment, respectively (see Table 2 [21] . The study by Berger et al. was the only study from a European perspective [26] , with analyses conducted separately for six countries. A major proportion of the total costs in the cisplatin-paclitaxel group was drug-related and in the cisplatin-cyclophosphamide group was hospitalization-related. The ICER estimate per LYG ranged from US$6395 in Spain to US$11,420 in Italy. Subsequently, after GOG-111 trial findings came to the forefront, the European Organization for Research and Treatment of Cancer (EORTC) 55931 trial [50] was designed to provide confirmatory findings and also integrate an economic evaluation with prospectively collected data on costs and quality of life. Using this source, Neymark et al. conducted a cost-effectiveness analysis from the perspective of the Belgian health insurance and financing system [27] . Patients randomized to cisplatin-paclitaxel gained an additional 4 months in mean survival, coupled with an added €7017 average cost per patient when Direct costs were estimated by adjusting local charges using a cost-to-charge ratio of 60 %. Laboratory and procedure costs were estimated in consultation with the University of Alabama at Birmingham. Pharmacy costs were calculated using average wholesale drug costs compared with the cisplatin-cyclophosphamide treatment arm. Paclitaxel cost was the major driver of the cost difference between both treatment arms; however, most patients in the cisplatin-cyclophosphamide group also received second-line paclitaxel treatment, which made overall drug acquisition costs nearly equivalent between the groups. An ICER of €20,385 per LYG was obtained. Using bootstrap simulation, the authors showed that for a threshold willingness-to-pay ranging between €12,400 and €24,800, the percentage of ICER replicates considered cost-effective would range between 20-60 %, respectively. In order to supplement decision making from trial-based evaluations, Limat et al. assessed the cost-effectiveness of paclitaxel using regular clinical practice data in a French university hospital before-and-after case study [28] . The year 1998 marked the change of standard treatment at their institution. The overall mean cost of treating a patient with cisplatin-paclitaxel was US$10,716 higher than with cisplatin-cyclophosphamide, with drug costs, hospitalization, and hematopoietic growth factors being the major cost drivers. With an incremental median benefit of 0.90 years and 0.78 quality-adjusted life-years (QALYs), the ICER for cisplatin-paclitaxel was estimated as US$11,907 per LYG and US$13,827 per QALY gained. Given the single site and small sample size (n = 59), extensive sensitivity analyses were carried out to examine uncertainties related to their cost and clinical parameters. Across the spectrum of variations, the ICER for cisplatin-paclitaxel remained less than US$20,000.
Intraperitoneal Compared with Intravenous Route of Administration (j = 2)
Administering adjuvant platinum-taxane chemotherapy via the intraperitoneal (IP) route over the traditional intravenous (IV) route was evaluated by two studies [29, 30] . Treatment arms that were compared in both studies were based on GOG-158 [51] and GOG-172 [52] protocols. While Bristow et al. [29] compared IV carboplatin-paclitaxel (from GOG-158) with IP cisplatin-paclitaxel (from GOG-172), Havrilesky et al. [30] additionally incorporated IV cisplatin-paclitaxel (from GOG-158) and IV cisplatinpaclitaxel (from GOG-172) in their analysis (Table 1) . Using a societal perspective, the ICERs for IP cisplatinpaclitaxel were estimated at US$60,976 and US$180,022 per QALY gained compared with IV carboplatin-paclitaxel in the studies by Bristow et al. and Havrilesky et al., respectively (see Table 2 for 2014 USD equivalent ICERs). The considerable differences in ICERs could be explained by differences in time horizon, survival time, source of cost data and number of completed intraperitoneal treatment cycles. Costs related to hospitalization for the IP administration and its related toxicities were the prime components of higher total costs in both studies. IV cisplatin-paclitaxel was dominated (more costly and less effective) compared with IV carboplatin-paclitaxel.
Targeted Biologics (j = 4)
Administration of a humanized anti-vascular endothelial growth factor antibody, such as bevacizumab, has gained popularity in the ovarian cancer treatment regimen because of its superior progression-free survival advantage observed in the GOG-218 and ICON-7 (Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7) trials [53, 54] . Using the earliest abstract findings from the GOG-218 trial, Cohn et al. [31] evaluated the cost-effectiveness of adding bevacizumab to standard platinum-taxane adjuvant chemotherapy in a simplified decision analysis model for a hypothetical cohort of 600 patients ( Table 1 ). The total cost of treatment increased across the three groups, ranging from carboplatin-paclitaxel (US$2. (Table 2) . Thus, adding bevacizumab to standard adjuvant chemotherapy was not a cost-effective alternative. When post-hoc subgroup analysis for the ICON-7 trial demonstrated that the high-risk stage IIIC/IV sub-group experienced an additional 8-month overall survival benefit with bevacizumab, Chan and colleagues conducted a cost-effectiveness evaluation to compare the standard combination carboplatinpaclitaxel treatment arm with the same combination with bevacizumab plus 12 cycles of maintenance bevacizumab [33] . The dose and duration of bevacizumab in this trial was shorter than GOG-218, impacting overall costs in their analyses. Using Medicare payments as their source of costs, the ICER for adding bevacizumab was estimated as US$167,771 per life-year saved (LYS) from a healthcare system perspective. At a willingness-to-pay threshold of US$200,000, only 37 % of their simulations were costeffective. To complement the earlier economic evaluations, Mehta and Hay assessed the cost-effectiveness of adding bevacizumab to first-line treatment from the perspective of US society [34] . Separate analyses were performed for an overall population based on the GOG-218 trial and a highrisk population based on the ICON-7 trial. (Table 2) . A strategy using concurrent bevacizumab plus maintenance bevacizumab for all patients and high-risk patients was dominated by the biomarker predictive test. Although administration of bevacizumab was more cost-effective in the high-risk population, it failed to fall within the traditional willingness-to-pay threshold.
Miscellaneous (j = 4)
Around the same period when most studies evaluated the economics of various platinum-taxane treatment strategies, Orr et al. assessed the cost-effectiveness of using an invitro drug resistance assay to guide individual chemotherapy for patients with stage III ovarian cancer after cytoreductive surgery [36] . Using average costs per patient and 3-year survival estimates from their primary phase II trial, cost-effectiveness for platinum-cyclophosphamide, platinum-paclitaxel, and assay-directed regimen was obtained by dividing total costs by 3-year survival. The costs per patient to obtain a 3-year survival were estimated as US$4615, US$17,988, and US$9768, respectively. The authors did not report on their source of cost data, comparison group, or any ICER estimates. Alternatively, Messori and colleagues evaluated the cost-effectiveness ratios for a high-dose treatment with hematopoietic rescue 
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(1) 30.9 w (2) 40.9 w (3) 34.2 w (using peripheral blood stem cell reinfusion or autologous bone marrow transplantation), conventional dose cisplatin, and cisplatin-paclitaxel [55] . With no survival difference found in their analyses between cisplatin and cisplatinpaclitaxel, the investigators did not report any cost-effectiveness ratio for these treatment alternatives [55] . However, the high-dose treatment with hematopoietic rescue yielded an ICER of US$25,641 per LYG compared with the conventional cisplatin regimen. Dalton et al. evaluated the cost-effectiveness of administering dose-dense weekly paclitaxel plus carboplatin compared with paclitaxel plus carboplatin every 3 weeks in patients with advanced ovarian cancer [37] . The treatment regimen with dosedense paclitaxel yielded an incremental cost and effect of US$2401 and 0.41 PFY, respectively, with an ICER of US$5809 per PFLY gained, well within the traditional willingness-to-pay thresholds. The cost-utility of platinumbased chemotherapy using community level data was evaluated in one study [38] . Lairson et al. used the Surveillance Epidemiology and End Results (SEER) Medicare-linked database to assess the cost-effectiveness of using only a platinum-based regimen versus a platinumtaxane combination and other non-platinum regimens in a large US cohort of elderly patients. The investigators found that compared with the no-chemotherapy group, the ICERs for the only platinum-based regimen were US$30,073 per QALY and US$58,151 per QALY for early-and late-stage disease, respectively. Use of a platinum-taxane combination and other non-platinum chemotherapy was dominated. The investigators used a propensity-score matched cohort to minimize selection bias and confounding resulting from their observational study design. They addressed methodological uncertainty by incorporating alternative scenarios for utility and a net-benefit approach.
Maintenance Therapy
Cost-effectiveness of maintenance therapy was evaluated in one study [39] . Although randomized controlled trials for maintenance therapy have shown promising improvements in progression-free survival, toxicity concerns and lack of an overall survival advantage have limited its wide acceptance. The study evaluated the cost-effectiveness of consolidation treatment with paclitaxel compared with bevacizumab in patients with advanced stage ovarian cancer that had undergone standard cytoreductive surgery followed by six cycles of adjuvant carboplatin-paclitaxel chemotherapy. Survival estimates were derived from three different trials and utility values from inputs by gynaecological oncology experts. With an ICER of US$13,402 per QALY, maintenance therapy with paclitaxel was cost-effective at the willingness-to-pay threshold of US$100,000 per QALY, from the US healthcare system perspective as compared with no maintenance therapy. In addition, it dominated bevacizumab maintenance therapy; that is, maintenance therapy with bevacizumab was more costly and less effective compared with paclitaxel maintenance therapy.
Second-Line Chemotherapy
Recurrent Platinum-Sensitive Disease
Patients that relapse after 6 months of completing a firstline platinum-based regimen are assumed to be platinumsensitive and usually offered subsequent platinum therapy.
We identified five studies with varying second-line treatment regimens that had a platinum agent in one of its treatment arms. The first study compared a regimen containing carboplatin only, carboplatin-paclitaxel, and carboplatin-gemcitabine [45] . The ICER for carboplatinpaclitaxel was estimated as US$15,564 per PFLY gained compared with carboplatin alone, making it a cost-effective second-line regimen. In contrast, the ICER for carboplatingemcitabine was substantially higher at US$278,388 per PFLY gained, compared with carboplatin-paclitaxel. In another study, Havrilesky et al. evaluated the cost-utility of administering concurrent versus sequential platinum-taxane chemotherapy [42] . The ICER for concurrent carboplatin-docetaxel was US$25,239 per QALY compared with sequential carboplatin-docetaxel, suggesting it was a cost-effective alternative from a third-party payer perspective. In the third study, Main et al. compared a range of treatment alternatives for use in patients with platinumsensitive disease [46] . The investigators derived clinical estimates from multiple trials, and their model comprised pegylated liposomal doxorubicin (PLD) hydrochloride, topotecan, paclitaxel monotherapy, cyclophosphamidedoxorubicin-cisplatin combination therapy (CAP), paclitaxel-platinum combination therapy and platinum-based monotherapy. Since topotecan, paclitaxel monotherapy, and PLD hydrochloride were all dominated by platinumbased monotherapy, these regimens were excluded in their analyses. Compared with platinum-based monotherapy, the ICER for CAP was £16,421 per QALY, and compared with CAP, the ICER for paclitaxel-platinum combination therapy was £20,950 per QALY. Lee et al. evaluated the costutility of carboplatin-PLD compared with carboplatin-paclitaxel as a second-line treatment strategy [41] . Using a Korean societal perspective, treatment with carboplatin-PLD incurred an incremental US$894 cost and 0.04 extra QALYs per patient. The resulting ICER was US$21,658 per QALY, and at a willingness-to-pay of US$20,000 (Korean GDP per capita in 2010), there was 49.4 % probability that carboplatin-PLD was cost-effective. The fifth study by Case et al. evaluated various chemotherapeutic strategies administered as second-line or subsequent treatment for patients with recurrent platinumsensitive ovarian cancer [44] . Best supportive care, secondline mono-chemotherapy (carboplatin), second-line combination chemotherapy (carboplatin-paclitaxel), two thirdline chemotherapy regimens (doxorubicin) and two fourthline regimens (gemcitabine) were compared in a decision model for a hypothetical cohort of 10,000 patients. Overall survival estimates were used from clinical experience and multiple phase II/III trials, while costs were incorporated for drugs and administration. There was a significant increase in total treatment costs as the line of treatment advanced (incremental costs were 161 million, 116 million, 220 million, and 406 million for second-line monotherapy, second-line combination, third-line previous combination, and fourth-line previous combination therapy, respectively); though the corresponding improvement in overall survival was poor (incremental overall survival rates were 8 months, 3 months, 4 months and 3 months, respectively). With ICERs of US$24,228 per LYG and US$46,068 per LYG, second-line mono-and combination therapies emerged as cost-effective strategies compared with best supportive care.
Patients that experience severe toxicities from platinumbased treatment or those considered to be partially platinum-sensitive (relapse within 6-12 months) may not benefit from second-line platinum-based treatment. The OVA-301 trial [56] was designed to compare use of PLD plus trabectedin with PLD alone in this population. Clinical parameters from this trial were used in two cost-effectiveness studies [40, 43] , one from the UK National Health Service/Personal Social Services perspective and the other from the Spanish National Health Service perspective. The incremental costs for treating patients with PLD plus trabectedin were £18,476 and €22,501, respectively, for a total 0.49 QALYs gained in both studies. The corresponding ICERs were estimated as £38,026 per QALY and €45,592 per QALY. Both studies concluded that the costeffectiveness of PLD plus trabectedin was debatable based on these ICER estimates, and dependent on the healthcare payers' willingness-to-pay.
Recurrent Platinum-Resistant Disease
Treating patients that relapse within 6 months of completing standard therapy (i.e., cytoreductive surgery ? adjuvant platinum-taxane chemotherapy) is an on-going challenge, given that overall survival in this cohort of platinum-resistant advanced ovarian cancer patients is \12 months. Rocconi et al. compared best supportive care, second-line mono-chemotherapy (doxorubicin), second-line combination chemotherapy (gemcitabine-cisplatin), and two third-line chemotherapy regimens (topotecan) [47] . Survival estimates were ascertained from several clinical trials and cost-estimates were derived for the drug and its administration. The investigators did not consider costs for treating chemotherapyrelated toxicities or complications. For their hypothetical cohort of 4000 patients, administration of best supportive care was the most cost-effective salvage therapy. Increasing the subsequent line of treatment translated into substantial cost with minimal improvement in overall survival. Second-line monotherapy with doxorubicin presented an ICER of US$64,104 per LYG, making it the next most cost-effective strategy contingent on the payer's willingness-to-pay threshold. All other higher-line treatments were either dominated or resulted in non-cost-effective ICERs.
Multiple-Line Chemotherapy Regimen
With evidence from clinical trials showing that first-line platinum-taxane combination chemotherapy was as efficacious as first-line platinum monotherapy, and limited considerations for subsequent second-line regimens, Fedders et al. designed a study to assess the cost-effectiveness of multiple-line chemotherapy regimens [48] . The authors evaluated carboplatin followed by topotecan, carboplatin followed by liposomal doxorubicin, carboplatin-paclitaxel followed by topotecan, and carboplatin-paclitaxel followed by liposomal doxorubicin as the alternative arms of their Markov model for a cohort of epithelial ovarian cancer patients staged from I-IV. They used clinical estimates from seven published trials and cost estimates from a University hospital in Germany. Although the study did not report the ICERs, the cost per LYS for the different treatment alternatives was estimated as €7892, €8270, €11,454, and €11,958, respectively. Considering a social willingness-to-pay threshold of €45,000 per LYG, all treatment regimens were deemed cost-effective. Notably, this study also lacked an explicit perspective as well as any sensitivity analyses.
Other Treatment Regimens
Significant limitations identified in a review evaluating economic evidence for PLD hydrochloride, topotecan, and paclitaxel led to the design of a cost-effectiveness study by Main et al. [46] . The investigators compared PLD hydrochloride, topotecan, and paclitaxel administered as a monotherapy for second-line or subsequent treatment of patients with platinum-sensitive, -refractory and -resistant advanced ovarian cancer. Compared with paclitaxel, the ICER for PLD hydrochloride was estimated as £7033 per QALY in the overall patient population, £5777 per additional QALY in the platinum-sensitive population, and £9555 per additional QALY in the platinum-resistant andrefractory population; while topotecan use was dominated by PLD hydrochloride overall and in the sub-group analysis. The probability of PLD hydrochloride being cost-effective for the overall population was 69-92 %, when the willingness-to-pay threshold ranged between £10,000 and £50,000 per additional QALY, respectively.
Sensitivity Analyses
One-way sensitivity analyses were performed in a majority of the studies and some more recent studies have also conducted probabilistic sensitivity analyses. Overall survival, progression-free survival and costs were varied across a range of values, specifically to determine the value at which cost-effectiveness for a treatment alternative may be reached. Alternatively, some studies also varied model probabilities, discount rate, utilities/quality-of-life indexes, infusion time for paclitaxel, and toxicity rates. Survival estimates were mostly varied in the ranges of ±25-75 %, while cost estimates were varied by ±20-30 %. Rarely were these ranges justified by prior evidence. The results of the studies that evaluated first-line platinum-taxane treatment were robust to the sensitivity analyses that were performed, and conclusions were not affected by the range of values examined. The ICER estimates for studies that evaluated bevacizumab were sensitive to cost and survival estimates [31, 33, 34] . In the first-line setting, bevacizumab would become cost-effective if its cost was to decline to approximately 50 % of the current cost [32, 34] , while in the maintenance therapy setting, its cost would have to decline to \12 % of its current cost for it to be cost-effective [39] . The findings for three studies that evaluated second-line treatment for platinum-sensitive recurrent disease were sensitive to changes in clinical parameters [40, 41, 45] . There was only one study that did not report sensitivity analyses [48] .
Quality Assessment
Quality assessment using the QHES instrument for all studies is shown in Table 3 . Of the 28 studies reviewed, 14 with a time horizon of [1 year discounted both costs and effectiveness. Quality-of-life adjustment due to treatments administered and associated adverse events was carried out for 13 studies. Three studies used utility values estimated from Functional Assessment of Cancer Therapy-General/ Ovarian quality of life questionnaire [29, 30, 42] , while Barnett et al. assessed utilities from the EORTC quality of life questionnaire [32] . Two studies evaluating treatments among platinum-sensitive ovarian cancer patients applied utilities obtained from the OVA-301 study which utilized the EuroQol EQ-5D questionnaire [40, 43] . Five studies obtained the utilities from the literature, three of which used a study by Havrilesky et al. that assessed health state utilities for ovarian cancer patients using the visual analog score and time trade-off method [34, 38, 39, 41, 46] . Ortega et al. estimated the health state utilities by conducting interviews of 40 subjects using the time trade-off technique [25] , while Limat et al. computed QALYs by adapting the quality-adjusted time without symptoms or toxicity (QTWiST) methodology and assumed a utility of 0.5 for the phase with toxicity and from progression to death [28] .
Clinical effectiveness (i.e., progression-free life-years, life-years, or quality-adjusted life-years) was estimated from clinical trial data for 25 studies, limiting the generalizability of the cost-effectiveness evaluations. Three studies used observational data to evaluate cost-effectiveness of primary treatment in the US [38] , France [28] , and Canada [22] . Lairson et al. used longitudinal populationbased registry data from various geographic areas in the US to estimate overall survival [38] . Limat et al. estimated overall survival for patients treated in a French university hospital using a before-after study design, while Covens et al. obtained survival information from patient charts at a cancer center in Canada [22, 28] . Almost all studies stated (89 %) a perspective, of which four studies considered a societal perspective. Two studies considered wages lost along with caregiver costs [29, 34] , one study only included caregiver cost [30] , and the remaining study considered only transportation costs [41] . Direct costs most commonly included were related to treatment (i.e., drug cost), treatment administration, hospitalization, and adverse events. However, only 19 studies included all of the above-mentioned costs in their analyses. A mix of micro-costing and gross-costing approaches were used with cost data estimated from fee schedules [22-24, 26, 27, 34, 40, 41, 45, 46] , hospitals [22-25, 28, 44, 47, 48] , Medicare reimbursement data [30-32, 38, 39, 42, 45] , secondary databases (e.g., Agency for Healthcare Research and QualityHealthcare Cost and Utilization Project) [29, 30, 32, 39, 43] , and literature [21, 34, 37, 46, 55] . Similarly, drug costs were obtained from various sources like hospitals [22, 23, 25, 29, 37, 48] , formularies or fee schedules [24, 26, 34, 40, 41, 43, 46] , Medicare reimbursement data [30, 31, 33, 37-39, 42, 45] , or average wholesale prices [28, 39, 44, 47] .
Discussion
Summary of Evidence
The evidence from eighteen CEAs for first-line treatment can be broadly categorized as fourteen studies incorporating platinum-taxane chemotherapy only and four studies that also include targeted biologics such as bevacizumab.
Eight of the fourteen studies specifically assessed the costeffectiveness of combination cisplatin-paclitaxel compared with cisplatin-cyclophosphamide [21] [22] [23] [24] [25] [26] [27] [28] . Paclitaxel was universally associated with an increase in costs and effectiveness, with a majority of these studies explicitly recommending cisplatin-paclitaxel as a cost-effective treatment option for advanced ovarian cancer. Two studies evaluated administration of IP cisplatin-paclitaxel compared with IV carboplatin-paclitaxel. While the approach showed good value in one study [29] , contradictory findings were obtained for the other [30] . In addition, alternative strategies such as use of in-vitro drug resistance assay to guide chemotherapy [36] , high-dose treatment with hematopoietic rescue [55] , and dose-dense weekly paclitaxel administration [37] were also considered costeffective compared with standard platinum-taxane regimen, cisplatin regimen, and 3-weekly paclitaxel, respectively. In one study that focussed solely on the elderly population, the platinum-based regimen was cost-effective compared with no chemotherapy for both early-and latestage disease [38] . Studies unanimously agreed that it is not cost-effective to include bevacizumab as a front-line treatment compared with the existing platinum-taxane standard for the overall ovarian cancer population [31] [32] [33] [34] . Nevertheless, two studies showed that in the high-risk subgroups, use of bevacizumab may yield better value than treating all patients [32, 33] . Also, bevacizumab will become off-patent in 2019 in the U.S., which may alter its a Applicable to only 2 of the articles reviewed cost-effectiveness [57] . For maintenance therapy, paclitaxel administration was cost-effective compared with no maintenance therapy [39] . Second-line treatment studies were categorized into recurrent platinum-sensitive (seven studies) and one platinum-resistant disease study. Varying regimens in the platinum-sensitive disease scenario were evaluated, with a majority of studies including a platinum-taxane agent in one treatment arm. Three studies concluded that secondline platinum-paclitaxel was a cost-effective treatment option (carboplatin was the platinum agent for two studies [44, 45] and unknown in the third study [46] ). Comparison groups for these studies were carboplatin alone [45] , bestsupportive care [44] , and cisplatin alone [46] , respectively. The use of carboplatin monotherapy was also cost-effective compared with best supportive care [44] . Similarly, carboplatin-PLD and concurrent carboplatin-docetaxel emerged as more cost-effective alternatives than carboplatin-paclitaxel [41] and sequential carboplatin-docetaxel [42] , respectively. For patients with partially platinumsensitive disease that may not fully benefit from platinumbased second-line treatment, the cost-utility of PLD plus trabectedin was compared with PLD alone in two studies [40, 43] . ICERs from both studies were high and costeffectiveness was dependent on the payer's willingness-topay above commonly cited benchmarks. In the setting of recurrent platinum-resistant disease, evidence showed that best supportive care was the most cost-effective strategy, followed by second-line monotherapy with doxorubicin [47] .
Only one study evaluating multiple-line chemotherapy regimens [48] concluded that first-line carboplatin followed by second-line topotecan, first-line carboplatin followed by second-line liposomal doxorubicin, first-line carboplatin-paclitaxel followed by second-line topotecan, and first-line carboplatin-paclitaxel followed by secondline liposomal doxorubicin were cost-effective treatment alternatives. In another study, PLD monotherapy emerged as cost-effective compared with paclitaxel or topotecan monotherapy for second-line or subsequent treatment of patients with platinum-sensitive, -refractory and -resistant advanced ovarian cancer [46] .
Quality of Evidence
The studies included in this review were published over a period of 18 years (1996-2014) and were conducted from various perspectives in several countries with different payment systems. Hence, direct comparison between studies was difficult. Nevertheless, general attributes such as health state utility sources, estimation of effectiveness and type of costs were evaluated. Only about half of the studies included in the review accounted for quality of life and thereby overall effectiveness of treatments may be overestimated. Moreover, effectiveness was primarily estimated using clinical trial data and thus more studies using real-world data may be needed to validate trial-based economic evaluations. While the societal perspective is the preferred perspective for economic evaluation, a majority of the studies excluded indirect costs which may underestimate total costs incurred by the patient and their family. A number of US-based studies estimated costs using Medicare reimbursement data, which may satisfactorily estimate costs for the elderly population (C65 years) but not for the younger, commercially insured population. Thus, cost-effectiveness results vary primarily due to the various approaches and multiplicity of sources from which costs were estimated.
Strengths and Limitations
To our knowledge, this is the first study to systematically review the cost-effectiveness literature on available chemotherapeutic alternatives and targeted biologics for ovarian cancer treatment. Contrary to previous systematic and narrative reviews that were outdated or restricted to a specific drug (e.g., paclitaxel) [58, 59] , this is the most comprehensive review incorporating economic evaluations over an extended period of time with quality assessed using a validated instrument. Additional strengths of this systematic review included the development of search strategies by a public health librarian with experience in systematic reviews (HVV). She worked in conjunction with the authors (IBP, RCP) to ensure that the appropriate terminology was employed. Both Medline (Ovid) and PubMed were searched even though they overlap significantly (Medline is a subset of PubMed); Embase (Ovid) was included to ensure that articles in journals with a nonNorth American focus were included. These databases include the vast majority of health economics publications. Great care was taken while screening to ensure each screener was blinded to the other's screening decisions. Additionally, each screener was blinded to article authors and publication journals to reduce the potential for bias. However, the results should be interpreted in light of certain limitations. Our study selection criteria did not include any population criteria in terms of age, ethnicity, residence, or tumor stage. However, a majority of the included studies were based on modeling, and estimates for the economic evaluations were derived from clinical trials. The average age of the population varied across the clinical trials; though a median age of approximately 56-60 years was reported for the commonly used GOG-111, GOG-218, ICON-7, and OVA-301 trials. Additionally, over 75 % of the studies comprised patients with an advanced stage (stage III or higher). Some relevant studies may have been overlooked in our review, especially those that were not published in the English language. Similarly, we did not formally assess potential publication bias that may have occurred due to the lack of inclusion of unpublished studies (e.g., industry-sponsored evaluations), which may have had unfavorable findings. Methodological quality of studies as well as reporting procedures have immensely improved over the last 2 decades, and it may not be appropriate to directly compare some of the older studies with those conducted more recently. While most studies mentioned their cost year, for some studies that did not, inflation adjustment or conversion using purchasing power parity was not conducted. In addition, to achieve more comparability across studies we excluded those that were partial economic evaluations, cost-minimization analyses, and cost-benefit analyses.
Conclusion
Based on the available evidence, we conclude that administration of cisplatin-paclitaxel combination chemotherapy for first-line treatment appears to be the most cost-effective alternative. Notably though, most of the first-line platinum-taxane economic evaluations were based on a cisplatin-paclitaxel treatment arm, despite carboplatin being the preferred platinum choice in clinical settings for almost a decade [5, 60, 61] . Given that carboplatin has a favorable side-effect profile and tolerability compared with cisplatin, it may be important to determine its position in the cost-effectiveness literature for ovarian cancer. Use of targeted biologics (e.g., bevacizumab) did not demonstrate similar value. With drug price changes and bio-similar products becoming available over the next decade, cost-effectiveness of biologics should be revisited. There was reasonable agreement that in patients with recurrent platinum-sensitive disease, administration of a second-line platinum-paclitaxel combination or platinum monotherapy was cost-effective compared with platinum monotherapy or best supportive care, respectively. In contrast, there was uncertainty if PLD plus trabectedin was cost-effective compared with PLD alone in patients with recurrent partially platinum-sensitive disease. Given the limited evidence, it was difficult to draw strong conclusions about treatment alternatives for patients with recurrent platinum-resistant disease. Nevertheless, it appears that best supportive care may be most cost-effective, followed by second-line monotherapy with doxorubicin.
